The Role of Estrogen Receptors in Urothelial Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Apr 2

PMID 33796076

Citations 15

Authors

Takuro Goto

Hiroshi Miyamoto

Affiliations

Soon will be listed here.

Abstract

Epidemiological data have indicated that there are some sex-related differences in bladder cancer. Indeed, the incidence of bladder cancer in men has been substantially higher than that in women throughout the world, while women tend to have higher stage disease and poorer prognosis. These gender disparities have prompted to investigate sex hormones and their cognitive receptors in bladder cancer. Specifically, estrogen receptors, including estrogen receptor-α and estrogen receptor-β, have been shown to contribute to urothelial carcinogenesis and cancer progression, as well as to modulating chemosensitivity in bladder cancer, although conflicting findings exist. Meanwhile, immunohistochemical studies in surgical specimens have assessed the expression of estrogen receptors and related proteins as well as its associations with clinicopathologic features of bladder cancer and patient outcomes. This review article summarizes and discusses available data indicating that estrogen receptor signaling plays an important role in urothelial cancer.

Citing Articles

The Estrogen-Autophagy Axis: Insights into Cytoprotection and Therapeutic Potential in Cancer and Infection.

Zhao Y, Klionsky D, Wang X, Huang Q, Deng Z, Xiang J Int J Mol Sci. 2024; 25(23).

PMID: 39684286 PMC: 11641569. DOI: 10.3390/ijms252312576.

GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer.

Tatenuma T, Matsukawa T, Goto T, Jiang G, Sharma A, Najafi M Cancer Genomics Proteomics. 2024; 21(6):557-565.

PMID: 39467629 PMC: 11534028. DOI: 10.21873/cgp.20472.

Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression.

Goto T, Teramoto Y, Nagata Y, Miyamoto H Discov Oncol. 2024; 15(1):440.

PMID: 39269616 PMC: 11399515. DOI: 10.1007/s12672-024-01324-2.

Genes Co-Expressed with Influence Clinical Outcomes in Cancer Patients: TCGA Data Analysis.

Lipowicz J, Malinska A, Nowicki M, Rawluszko-Wieczorek A Int J Mol Sci. 2024; 25(16).

PMID: 39201394 PMC: 11354723. DOI: 10.3390/ijms25168707.

Mineralocorticoid receptor signaling inhibits bladder cancer progression.

Nagata Y, Goto T, Teramoto Y, Matsukawa T, Fujimoto N, Miyamoto H Am J Cancer Res. 2024; 14(2):696-708.

PMID: 38455412 PMC: 10915320.

References

Ge Q, Lu M, Ju L, Qian K, Wang G, Wu C . miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer. Int J Cancer. 2018; 144(12):3043-3055. DOI: 10.1002/ijc.32036. View

Goldstein N, Ferkowicz M, Odish E, Mani A, Hastah F . Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003; 120(1):86-92. DOI: 10.1309/QPHD-RB00-QXGM-UQ9N. View

Kontos S, Kominea A, Melachrinou M, Balampani E, Sotiropoulou-Bonikou G . Inverse expression of estrogen receptor-beta and nuclear factor-kappaB in urinary bladder carcinogenesis. Int J Urol. 2010; 17(9):801-9. DOI: 10.1111/j.1442-2042.2010.02603.x. View

Bernardo C, Santos J, Costa C, Tavares A, Amaro T, Marques I . Estrogen receptors in urogenital schistosomiasis and bladder cancer: Estrogen receptor alpha-mediated cell proliferation. Urol Oncol. 2020; 38(9):738.e23-738.e35. DOI: 10.1016/j.urolonc.2020.04.022. View

Croft P, Lathrop S, Feddersen R, Joste N . Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma. Arch Pathol Lab Med. 2005; 129(2):194-9. DOI: 10.5858/2005-129-194-EREIPU. View

Dellagrammaticas D, Bryden A, Collins G . Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol. 2001; 165(5):1631. View

Hartge P, HARVEY E, Linehan W, Silverman D, Sullivan J, Hoover R . Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990; 82(20):1636-40. DOI: 10.1093/jnci/82.20.1636. View

Goto T, Kashiwagi E, Jiang G, Nagata Y, Teramoto Y, Baras A . Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer. Am J Cancer Res. 2020; 10(8):2523-2534. PMC: 7471368. View

Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J . The Estrogen Pathway: Estrogen Receptor-α, Progesterone Receptor, and Estrogen Receptor-β Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clin Genitourin Cancer. 2015; 13(5):476-84. DOI: 10.1016/j.clgc.2015.04.001. View

10.

Ou Z, Wang Y, Chen J, Tao L, Zuo L, Sahasrabudhe D . Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals. Exp Mol Med. 2018; 50(11):1-11. PMC: 6243995. DOI: 10.1038/s12276-018-0155-5. View

11.

Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota J, Moriyama M . Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget. 2016; 7(12):14153-60. PMC: 4924704. DOI: 10.18632/oncotarget.7358. View

12.

Soltysik K, Czekaj P . Membrane estrogen receptors - is it an alternative way of estrogen action?. J Physiol Pharmacol. 2013; 64(2):129-42. View

13.

Radkiewicz C, Edgren G, Johansson A, Jahnson S, Haggstrom C, Akre O . Sex Differences in Urothelial Bladder Cancer Survival. Clin Genitourin Cancer. 2019; 18(1):26-34.e6. DOI: 10.1016/j.clgc.2019.10.020. View

14.

Bolenz C, Lotan Y, Ashfaq R, Shariat S . Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol. 2009; 56(6):1093-5. DOI: 10.1016/j.eururo.2009.06.032. View

15.

Hsu C, Chen J, Wu C, Cheng A, Pu Y . Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 2001; 21(1B):711-5. View

16.

Kim H, Kim B, Kim I, Mamura M, Seong D, Jang J . Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem. 2002; 277(36):32510-5. DOI: 10.1074/jbc.M202852200. View

17.

Izumi K, Li Y, Ishiguro H, Zheng Y, Yao J, Netto G . Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinog. 2012; 53(4):314-24. DOI: 10.1002/mc.21978. View

18.

Zhang Z, Pak J, Shapiro E, Sun T, Wu X . Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999; 59(14):3512-7. View

19.

Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B . Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun. 2017; 8:15840. PMC: 5501969. DOI: 10.1038/ncomms15840. View

20.

Imai Y, Noda S, Matsuyama C, Shimizu A, Kamai T . Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer. Urol Oncol. 2019; 37(6):353.e9-353.e15. DOI: 10.1016/j.urolonc.2019.01.023. View